IP Library Granted Patent US 12,667,088
Granted Patent B2
US 12,667,088 · App. 17/956,771 · Granted Jun 30, 2026

Animal model of brain tumor and manufacturing method of animal model

Inventors: Seok Gu Kang (Suwon-si, KR); Jeong Ho Lee (Daejeon, KR); Joo Ho Lee (Daejeon, KR); Jeong Eun Lee (Daejeon, KR)
Assignees: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY; YONSEI UNIVERSITY, UNIVERSITY—INDUSTRY FOUNDATION (UIF)
A01K67/0276A01K2217/075A01K2217/15A01K2227/105A01K2267/0331
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,667,088
App. No.
17/956,771
Granted
Jun 30, 2026
Kind
B2
Abstract

The present invention relates to a brain tumor animal model that directly reflects the phenomenon in a human patient and a method of preparing the same, and more specifically, a brain tumor animal model that mutations are introduced into p53, Pten, and EGFR genes, a screening method of a therapeutic agent for a brain tumor using the animal model, and a preparing method thereof.

Claims (10)

1 . A transgenic mouse comprising,

knock-out mutations of p53 and Pten genes in nerve stem cells of subventricular zone (SVZ), and

an activating mutation of epidermal growth factor receptor (EGFR) gene in nerve stem cells of SVZ,

wherein a glioblastoma occurs in the dorsolateral-caudal cortex region,

wherein the glioblastoma develops from nerve stem cells that are positive for Glial fibrillary acidic protein (GFAP),

wherein the GFAP positive nerve stem cells have normal cytoarchitecture.

2 . The transgenic mouse of claim 1 , wherein the glioblastoma is a high-grade glioblastoma having characteristics of necrosis, microvascular proliferation and mitosis, and has an immune response to GFAP, Nestin, Olig2, and PDGFRα.

3 . The transgenic mouse of claim 1 , wherein the glioblastoma is IDH-wild type.

4 . The transgenic mouse of claim 1 , wherein the mouse maintains the knockout mutations of p53 and Pten genes specific to nerve stem cells in SVZ even after glioblastoma occurrence.

5 . The transgenic mouse of claim 1 , wherein the p53 gene comprises at least one nucleotide sequence of SEQ ID Nos: 38 to 40, and the Pten gene comprises at least g nucleotide sequence of SEQ ID Nos: 41 to 43.